GT Biopharma, Inc. (GTBP)
| Market Cap | 9.15M +281.2% |
| Revenue (ttm) | n/a |
| Net Income | -11.38M |
| EPS | -13.22 |
| Shares Out | 1.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 178,753 |
| Open | 5.49 |
| Previous Close | 5.46 |
| Day's Range | 5.07 - 5.78 |
| 52-Week Range | 4.91 - 28.75 |
| Beta | 0.86 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About GTBP
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product cand... [Read more]
Financial Performance
Financial StatementsNews
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics b...
GT Biopharma Proxy statement: Proxy filing
GT Biopharma filed a proxy statement on October 13, 2026, providing details for shareholder voting and corporate governance matters.
GT Biopharma registers to sell 13.5M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 13.5M shares of common stock. The company is not selling any…
GT Biopharma Registration statement: Registration filing
GT Biopharma filed a registration statement on October 9, 2026, providing details about a securities offering with the SEC.
GT Biopharma Proxy statement: Proxy filing
GT Biopharma filed a proxy statement on October 2, 2026, providing details for shareholder voting and corporate governance matters.
GT Biopharma trading halted, volatility trading pause
09:30 EDT GT Biopharma (GTBP) trading halted, volatility trading pause
GT Biopharma announces IND clearance from FDA for GTB-5550 in multiple myeloma
GT Biopharma (GTBP) announced IND clearance from the FDA for GTB-5550 in multiple myeloma. “Today’s IND to expand the potential indications for GTB-5550 highlights the diverse utility of our Trike(R)…
GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of n...
GT Biopharma Transcript: Status update
The TriKE platform is advancing in phase I trials for both blood cancers and solid tumors, showing promising early safety and efficacy signals. The technology's modular design enables rapid adaptation to new targets, with upcoming milestones including key data readouts and expansion into autoimmune disease.
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
SAN FRANCISCO, CALIFORNIA, Sept. 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics ...
GT Biopharma trading halted, news pending
19:50 EDT GT Biopharma (GTBP) trading halted, news pending
GT Biopharma Slides: Corporate presentation
GT Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on August 17, 2026.
GT Biopharma Reports Second Quarter 2026 Financial Results
Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with an update anticipated in 2H 2026
GT Biopharma Quarterly report: Q2 2026
GT Biopharma has published its Q2 2026 quarterly earnings report on August 14, 2026.
GT Biopharma Earnings release: Q2 2026
GT Biopharma released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
GT Biopharma Proxy statement: Proxy filing
GT Biopharma filed a proxy statement on July 2, 2026, providing details for shareholder voting and corporate governance matters.
GT Biopharma Proxy statement: Proxy filing
GT Biopharma filed a proxy statement on June 18, 2026, providing details for shareholder voting and corporate governance matters.
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tu...
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing develop...
GT Biopharma Reports First Quarter 2026 Financial Results
Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with additional updates anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE ® in multiple solid tumor types known to expres...
GT Biopharma Quarterly report: Q1 2026
GT Biopharma has published its Q1 2026 quarterly earnings report on May 15, 2026.
GT Biopharma Earnings release: Q1 2026
GT Biopharma released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
GT Biopharma doses first patient in GTB-5550 trial
GT Biopharma (GTBP) announced that the first patient was dosed in a Phase 1 dose escalation basket trial evaluating GTB-5550, its B7-H3-targeted natural killer (NK) cell engager for solid tumors…
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
GTB-5550 is now the 3rd TriKE ® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalati...